Increasing Gene Therapy Acceptance Boosts DNA Synthesizer Market

The DNA synthesizer market was USD 266.3 million in 2023, and it will increase to USD 686.1 million, with a 14.6% compound annual growth rate, by 2030.  

The growth is because of the increasing incidence of severe diseases, rising need for more-tailored therapies, growing gene therapy acceptance, and mounting funding in R&D. 

A drastic rise in the need for synthetic deoxyribonucleic acid has been witnessed across different research & commercial industries. Affiliated areas, for instance, biology, nanotechnology, data storage, and therapy are likely to display rapid expansion as DNA is presented at low costs and scale. 

Moreover, the swift acceptance of gene editing technologies like next-generation sequencing (NGS) and DNA synthesis, is also aiding the industry expansion. 

The pilot category, based on scale, accounted for the largest share in 2023, at 70%. This can be because of the benefits of pilot-scale DNA synthesizers like easy project quality measurement by assessing the project & process features, without worrying about a substantial financial loss. 

The research and development category, based on application, accounted for the largest DNA synthesizer market share in 2023, at 45%. This can be because deoxyribonucleic acid is the source of biotechnology-associated research. The bio-engineering area uses large quantities of synthetic DNA for research reasons. 

DNA Synthesizer Market

The therapeutics category will propel at the fastest rate, of 15.2%, in the years to come. DNA synthesizers assist in producing custom-made DNA molecules, which contain a specific nucleotide sequence. 

The biotechnology companies category, based on end users, held the largest share in 2023, of 50%. This can be because of the increasing biotechnology-associated research, owing to the surging need for biologic medications like vaccines. This can be further ascribed to the rising incidence of different non-contagious and contagious illnesses over the past few years. 

North America was the largest contributor to the industry. This is because of the existence of reputable players in this sector, strong biotechnology R&D activities, and robust backing for the formation of research & development facilities in this continent.  

Additionally, technological improvements in genomics, along with the launch of developed, customized therapies for different incurable conditions like cancer, will drive the need for DNA synthesizers. 

APAC is likely to propel at the fastest compound annual growth rate, of 15.2%, in the coming years. This can be ascribed to the increasing backing from the government for biologics research and drug discovery. Furthermore, the increasing need for the constant synthetic DNA supply for research purposes is also driving regional industry growth. 

It is because of the surge in the acceptance of gene therapy, the DNA synthesizer industry will continue to advance in the years to come. 

SOURCE: P&S Intelligence